Back to top
more

Mind Medicine MindMed (MNMD)

(Delayed Data from NSDQ)

$9.64 USD

9.64
1,303,145

+0.28 (2.99%)

Updated Aug 5, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

Zacks Equity Research

All You Need to Know About Mind Medicine MindMed (MNMD) Rating Upgrade to Buy

by Zacks Equity Research

Mind Medicine MindMed (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Wall Street Analysts Believe Mind Medicine MindMed (MNMD) Could Rally 237.47%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 279.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

MindMed Stock Skyrockets 94% Year to Date: What's Driving It?

by Zacks Equity Research

2024 was a transformational year for MNMD as it executed many important milestones.

Kinjel Shah headshot

5 Biotech Breakthrough Stocks to Watch in 2025

by Kinjel Shah

It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years

Zacks Equity Research

Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Mind Medicine MindMed (MNMD) This Year?

by Zacks Equity Research

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Zacks Equity Research

MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why

by Zacks Equity Research

MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.

Zacks Equity Research

MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.

Zacks Equity Research

What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock

by Zacks Equity Research

Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study

by Zacks Equity Research

MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

by Andrew Rocco

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Zacks Equity Research

Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.

Zacks Equity Research

Mind Medicine MindMed Inc. (MNMD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Mind Medicine MindMed Inc. (MNMD) closed at $2.80, marking a -1.41% move from the previous day.

Shrabana Mukherjee headshot

5 Top Stocks to Buy on New Analysts' Coverage

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Napco Security (NSSC), Proto Labs (PRLB), Clear Secure (YOU), AVEO and Mind Medicine (MNMD).

Zacks Equity Research

Wall Street Analysts Predict a 399% Upside in Mind Medicine MindMed Inc. (MNMD): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 399.3% upside potential for Mind Medicine MindMed Inc. (MNMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Why Earnings Season Could Be Great for Mind Medicine (MNMD)

by Zacks Equity Research

Mind Medicine (MNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Do Options Traders Know Something About MindMed (MNMD) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to MindMed (MNMD) stock based on the movements in the options market lately.